David Faber, MD
Retina Specialist · Salt Lake City, UTNPI 1811990450
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,640 of the $9,562 with a category attached, or 69.4%. 19 manufacturers reported payments, led by Genentech, Inc. at 30.9% of the total. Reporting peaked in 2019 at $4,502 and has fallen 75.4% since, to $1,109 in 2025.
Across 178 payments — averaging $53.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$1K
- Janssen Research & Development, LLC$908
- Eyepoint US, Inc.$470
- Alimera Sciences, Inc.$426
- plus $2K from 13 others
Across 146 payments — averaging $2807.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$358K
- Ocular Therapeutix, Inc.$27K
- Regeneron$8K
- F. Hoffmann-la Roche AG$7K
- Hexal AG$5K
- Janssen Research & Development, LLC$5K
What the payments were for
- Travel & lodging$2,88330%
- Food & beverage$6,64069%
- Gifts$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 9 | $2,956 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,817 |
| Genentech USA, Inc. | 33 | $1,090 |
| Janssen Research & Development, LLC | 12 | $908 |
| Eyepoint US, Inc. | 7 | $470 |
| Alimera Sciences, Inc. | 14 | $426 |
| AbbVie(2 entities) | 13 | $344 |
| Astellas Pharma US Inc | 11 | $317 |
| Harrow Eye, LLC | 8 | $300 |
| Alcon | 2 | $281 |
| Novartis | 5 | $262 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| ANI Pharmaceuticals, Inc. | 3 | $53 |
| Biogen | 3 | $53 |
| Hoffmann-la Roche Limited | 1 | $46 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Coherus Oncology, Inc. | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $27 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,562 in reported general payments places this provider in the 80th percentile of 20 retina specialist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 70 | $3,054 |
| Brimonidine Tartrate | 76 | $2,133 |
| Latanoprost | 113 | $1,215 |
| Timolol Maleate | 32 | $586 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 38 | $285 |
| Dorzolamide Hcl | 17 | $280 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $150 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Salt Lake City
- Robert KwunSalt Lake City$334K
- Mitchell GoffSalt Lake City$165K
- James HowardSalt Lake City$14K
- Rebekah GensureSalt Lake City$5K
- Kirk WinwardSalt Lake City$3K
- Eric BrintonSalt Lake City$3K
- Gregory BrintonSalt Lake City$1K
- Mano SwartzSalt Lake City$28
- Andrew DavisWest Jordan$4K
- Joshua CarlsonSt George$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.